InvestorsHub Logo
Followers 2
Posts 333
Boards Moderated 0
Alias Born 07/19/2016

Re: equaloppforall post# 58567

Saturday, 03/10/2018 8:59:38 AM

Saturday, March 10, 2018 8:59:38 AM

Post# of 108192
An interesting quote, equal:

All this being said, I think a bunch of us are in agreement that small cap biotechs are no longer fit for "investment" in this corrupt, HFT driven market



Corrupt, certainly. HFT, certainly. However, knowing the game makes it a bit easier the second time around. We've all learned a lot from the last years, some of us having been here close to a decade. If this plays out the way many here hope, that is Advaxis not being sold, at least not before axal is approved, we will have 20/20 hindsight to guide us in the future.

Picture this. Another as yet untapped platform, treating widespread disease with multiple billions in yearly potential revenue, saving and prolonging lives. Do you want to be a part of that?

A small company, the founder to the science working for decades on it. Public company, and knockoffs from BP. Clinical trials always promising, little to no adverse effects, cheap to manufacture. Synergistic with other treatments, improving efficacy. Identifiable biomarkers, helping get the treatment to the correct patients.

You invest, and eventually see a nice run up, a 10 even a 15 bagger. Then you see increasing short numbers and what appears to be HFT. But your experience with Advaxis is solidly in your mind, so you sell or protect with out of the money puts, perhaps even short for the ride down if you're more certain. Not doing this was the mistake many, but not all, of us made. We didn't protect, we believed the science would prevail, and it will, but not in the way we wanted.

I think it's ok to speculate again in baby bio's. Experience is a powerful teacher.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News